Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides

Cellular and Molecular Life Sciences

Volumn 67, Issue 5, 2010, Pages 715-726

  Said Hassane, F ^a   Saleh, A F ^b   Abes, R ^a   Gait, M J ^b   Lebleu, Bernard ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Cell penetrating peptides; Drug delivery; Nucleic acids delivery

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DYSTROPHIN; INSULIN; LIPOSOME; OLIGOMER; OLIGONUCLEOTIDE; PACLITAXEL; PENETRATIN; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER DERIVATIVE; PROTEIN BCL 2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; PEPTIDE;

AMINO ACID SEQUENCE; BECKER MUSCULAR DYSTROPHY; BINDING SITE; BIOAVAILABILITY; CELL MEMBRANE; CONJUGATION; COVALENT BOND; DOWN REGULATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOCYTOSIS; GENE MUTATION; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HYDROPHOBICITY; INTERNALIZATION; INTRON; IRRADIATION; MOLECULAR WEIGHT; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; GENE TRANSFER; METABOLISM;

ANIMALIA;

ANIMALS; CELL MEMBRANE PERMEABILITY; CELLS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES; PEPTIDES;

EID: 77949890248     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-009-0186-0     Document Type: Review

References (99)

1. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193
2. Joliot AH, Triller A, Volovitch M, Pernelle C, Prochiantz A (1991) alpha-2, 8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide. New Biol 3:1121-1134
3. 3. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450 (Pubitemid 24198241)
4. 4. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J Biol Chem 272:16010-16017 (Pubitemid 27265584)
5. 5. Joliot A, Prochiantz A (2008) Homeoproteins as natural Penetratin cargoes with signaling properties. Adv Drug Deliv Rev 60:608-613 (Pubitemid 351215577)
6. 6. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730-2736 (Pubitemid 27299785)
7. Pooga M, Hallbrink M, Zorko M, Langel U (1998) Cell penetration by transportan, FASEB J 12:67-77
8. 8. Morris MC, Deshayes S, Heitz F, Divita G (2008) Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 100:201-217 (Pubitemid 351517084)
9. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH (2008) The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 60:452-472
10. Asoh S, Ohta S (2008) PTD-mediated delivery of anti-cell death proteins/peptides and therapeutic enzymes, Adv Drug Deliv Rev 60:499-516
11. 11. Cantara S, Thorpe PE, Ziche M, Donnini S (2007) TAT-BH4 counteracts Abeta toxicity on capillary endothelium. FEBS Lett 581:702-706 (Pubitemid 46216296)
12. Ono M, Sawa Y, Ryugo M, Alechine AN, Shimizu S, Sugioka R, Tsujimoto Y, Matsuda H (2005) BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough antiapoptotic mechanism in rat hearts. Eur J Cardiothorac Surg 27:117-121
13. 13. Bright R, Raval AP, Dembner JM, Perez-Pinzon MA, Steinberg GK, Yenari MA, Mochly-Rosen D (2004) Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci 24:6880-6888 (Pubitemid 39045444)
14. 14. Ikeno F, Inagaki K, Rezaee M, Mochly-Rosen D (2007) Impaired perfusion after myocardial infarction is due to reperfusioninduced deltaPKC-mediated myocardial damage. Cardiovasc Res 73:699-709 (Pubitemid 46227353)
15. 15. Chen L, Harrison SD (2007) Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem Soc Trans 35:821-825 (Pubitemid 47310376)
16. 16. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664-668 (Pubitemid 24041462)
17. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572
18. Murriel CL, Dowdy SF (2006) Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3:739-746
19. Edenhofer F (2008) Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins. Curr Pharm Des 14:3628-3636
20. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K (2008) Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21-25
21. 21. Brunet I, Di Nardo AA, Sonnier L, Beurdeley M, Prochiantz A (2007) The topological role of homeoproteins in the developing central nervous system, Trends Neurosci 30:260-267 (Pubitemid 46802831)
22. Goun EA, Pillow TH, Jones LR, Rothbard JB, Wender PA (2006) Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. Chembiochem 7:1497-1515
23. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA (2008) Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci USA 105:12128-12133
24. McCarthy JR, Weissleder R (2008) Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241-1251
25. 25. Josephson L, Tung CH, Moore A, Weissleder R (1999) Highefficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 10:186-191 (Pubitemid 29147720)
26. Torchilin VP (2008) Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90:604-610
27. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T, Bartfai T, Langel U (1998) Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 16:857-861
28. Juliano R, Bauman J, Kang H, Ming X (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6:686-695
29. Kang SH, Cho MJ, Kole R (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37:6235-6239
30. Sazani P, Kang SH, Maier MA, Wei C, Dillman J, Summerton J, Manoharan M., Kole R (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 29:3965-3974
31. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B (2006) Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release 110:595-604
32. Shiraishi T, Pankratova S, Nielsen PE (2005) Calcium, ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic tat and oligoarginine peptides. Chem Biol 12:923-929
33. 33. Boe S, Hovig E (2006) Photochemically induced gene silencing using PNA-peptide conjugates. Oligonucleotides 16:145-157 (Pubitemid 43912115)
34. 34. Shiraishi T, Nielsen PE (2006) Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Lett 580:1451-1456 (Pubitemid 43222014)
35. 35. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA (2002) Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45:3612-3618 (Pubitemid 34856101)
36. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B (2006) Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116:304-313
37. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A, Clair P, Gait MJ, Lebleu B (2007) Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide, Nucleic Acids Res 35:4495-4502
38. Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, Prevot P, Youngblood DS, Iversen PL, Chemomordik LV, Lebleu B (2008) Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 36:6343-6354
39. Burrer R, Neuman BW, Ting JP, Stein DA, Moulton HM, Iversen PL, Kuhn P, Buchmeier MJ (2007) Antiviral effects of antisense morpholino oligomers in murine Coronavirus infection models. J Virol 81:5637-5648
40. Turner JJ, Ivanova GD, Verbeure B, Williams D, Arzumanov AA, Abes S, Lebleu B, Gait MJ (2005) Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res 33:6837-6849
41. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B, Gait MJ (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36:6418-6428
42. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, Iversen PL, Arzumanov AA, Gait MJ (2008) Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60:517-529
43. Mae M, El Andaloussi S, Lundin P, Oskolkov N, Johansson HJ, Guterstam P, Langel U (2009) A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 134:221-227
44. Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27:567-571
45. Crombez L, Morris MC, Dufort S, Aldrian-Herrada G, Nguyen Q, McMaster G, Coll J-L, Heitz F, Divita G (2009) Targeting cycling B through peptide-based delivery of siRNA prevents tumor growth, Nucleic Acids Res (in press)
46. 46. Aartsma-Rus A, van Ommen GB (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609-1624 (Pubitemid 47481669)
47. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyanopoulos P, Garraldi EM, Rutherford M, Mcculley C, Popplewell LJ, Graham IR, Dickson G, Wood M, Wells DJ, Wilton SD, Holt T, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a singleblind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918-928
48. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GB (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. New England J Med 357:2677-2686
49. 49. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured radx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7:1083-1090 (Pubitemid 28306871)
50. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98:42-47
51. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin HF, Alter J, Jadoon A, Bou-Gharios G, Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198-203
52. 52. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8:207-216 (Pubitemid 43250701)
53. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177
54. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD (2007) Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 151:587-592
55. 55. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iversen P, Wood MJA (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909-3918 (Pubitemid 352762853)
56. Jearawiriyapaisam N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL, Kole R (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16:1624-1629
57. Wu B, Moulton HM, Iversen PL, Juang J, Li J, Spurney CF, Sali A., Guerron AD, Nagaraju K, Doran T, Lu P, Xiao X, Lu QL (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modifies morpholino oligomer. Proc Natl Acad Sci USA. 105:14814-14819
58. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iversen PL, Wood MJA (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice, Hum Mol Genet (in press)
59. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJA, Lebleu B, Gait MJ (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36:6418-6428
60. 60. Drin G, Mazel M, Clair P, Mathieu D, Kaczorek M, Temsamani J (2001) Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity. Eur J Biochem 268:1304-1314 (Pubitemid 32231883)
61. 61. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chemomordik LV, Lebleu B (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585-590 (Pubitemid 36043612)
62. 62. Lundberg M, Johansson M (2002) Positively charged DNAbinding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 291:367-371 (Pubitemid 34694414)
63. 63. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chemomordik LV (2005) Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280:15300-15306 (Pubitemid 40562886)
64. 64. Drin G, Demene H, Temsamani J, Brasseur R (2001) Translocation of the pAntp peptide and its amphipathic analogue AP-2AL. Biochemistry 40:1824-1834 (Pubitemid 32144055)
65. 65. Torchilin VP, Rammohan R, Weissig V, Levchenko TS (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 98:8786-8791 (Pubitemid 32678105)
66. 66. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G (2004) OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta 1665:48-56 (Pubitemid 39303569)
67. Ter-Avetisyan G, Tunnemann G, Nowak D, Nitschke M, Herrmann A, Drab M, Cardoso MC (2009) Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem 284:3370-3378
68. 68. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8:848-866 (Pubitemid 46971632)
69. Vives E, Granier C, Prevot P, Lebleu B (1997) Structure activity relationship study of the plasma membrane translocating potential of a short peptide of HIV-1 Tat protein. Lett Pept Sci 4:1-8
70. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K (2003) Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278:35109-35114
71. Potocky TB, Menon AK, Gellman SH (2003) Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J Biol Chem 278:50188-50194
72. 72. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B (2004) HIV-1 Tat enters T cells using coated pits before translocating from, acidified endosomes and eliciting biological responses. Mol Biol Cell 15:2347-2360 (Pubitemid 38580651)
73. 73. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram. F, Giacca M (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278:34141-34149 (Pubitemid 37553255)
74. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315
75. Kaplan IM, Wadia JS, Dowdy SF (2005) Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102:47-253
76. Foerg C, Merkle HP (2008) On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 97:144-162
77. 77. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101:17867-17872 (Pubitemid 40051978)
78. 78. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836-5840 (Pubitemid 37385738)
79. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56:318-325
80. Oehlke J, Seheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M, Bienert M (1998) Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1414:127-139
81. 81. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57:579-596 (Pubitemid 40255562)
82. Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H, Fujita S, Hayakawa T, Takeda K, Hasegawa M, Nakanishi M (2001) Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J Biol Chem 276:26204-26210
83. Snyder EL, Dowdy SF (2001) Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 3:147-152
84. Kersemans V, Kersemans K, Cornelissen B (2008) Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des 14:2415-2447
85. 85. Bhorade R, Weissleder R, Nakakoshi T, Moore A, Tung CH (2000) Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjug Chem 11:301-305 (Pubitemid 30324895)
86. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D (2000) Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 11:762-771
87. 87. Torchilin VP (2008) Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548-558 (Pubitemid 351215572)
88. 88. Rudolph C, Schillinger U, Ortiz A, Tabatt K, Plank C, Muller RH, Rosenecker J (2004) Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res 21:1662-1669 (Pubitemid 41184398)
89. de la Fuente JM, Berry CC (2005) Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 16:1176-1180
90. Sethuraman VA, Bae YH (2007) TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 118:216-224
91. Tseng YL, Liu JJ, Hong RL (2002) Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 62:864-872
92. Torchilin VP, Levchenko TS (2003) TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 4:133-140
93. 93. Kirschberg TA, VanDeusen CL, Rothbard JB, Yang M, Wender PA (2003) Arginine-based molecular transporters: the synthesis and chemical evaluation of releasable taxol-transporter conjugates. Org Lett 5:3459-3462 (Pubitemid 37487437)
94. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6:1253-1257
95. Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait MJ, Iversen P, Lebleu B (2008) Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14:455-460
96. Veldhoen S, Laufer SD, Restle T (2008) Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci 9:1276-1320
97. 97. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U (2001) Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 1515:101-109 (Pubitemid 33086827)
98. Corradin S, Ransijn A, Corradin G, Bouvier J, Delgado MB, Fernandez-Carneado J, Mottram JC, Vergeres G, Mauel J (2002) Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J 367:761-769
99. 99. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D (2001) The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion, Cancer Res 61:1768-1775 (Pubitemid 32691981)